Edgewise Therapeutics (EWTX) presents Topline results from the Phase 1b study of EDG-5506 - Slideshow

| --- | |-------| | | | | | | CONFIDENTIAL Our vision is to improve the lives of patients and families suffering from rare muscle disorders NASDAQ: EWTX Forward-Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties of Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"). All statements other than statements of historical facts contained in this presentation, including statements regarding our future financial condition, results of oper ...